{
    "nct_id": "NCT03424122",
    "official_title": "A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",
    "inclusion_criteria": "* Men and women, aged 18 years or older on the day of signing the Informed Consent Form (ICF).\n* Histologically confirmed indolent/aggressive DLBCL, FL, MZL, or MCL.\n* Participants with DLBCL, MZL or MCL must have received at least 1 prior line of systemic therapy with documented progression or documented failure to achieve CR or PR after the most recent systemic treatment regimen.\n* Participants with FL must have received at least 2 prior lines of systemic therapy with documented progression or documented failure to achieve CR or PR after the most recent systemic treatment regimen.\n* Ineligible for stem cell transplant.\n* Participants with DLBCL must have failed or refused stem cell transplantation or failed first-line salvage therapy if ineligible for transplantation.\n* Must be willing to undergo an incisional or excisional lymph node or tissue biopsy or to provide a lymph node or tissue biopsy from the most recent available archival tissue.\n* Life expectancy of > 3 months.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2 (see Appendix D).\n* Willingness to avoid pregnancy or fathering a child.\n* Ability to comprehend and willingness to sign an ICF\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Evidence of transformed non-Hodgkin lymphoma histologies (with the exception of FL).\n* Histologically confirmed rare non-Hodgkin B-cell subtypes.\n* History of or central nervous system lymphoma (either primary or metastatic) or leptomeningeal disease.\n* Prior treatment with idelalisib, other selective PI3KÎ´ inhibitors, or a pan-PI3K inhibitor.\n* For participants to be treated with bendamustine (Treatment B), prior treatment with bendamustine (within 12 months of the start of study treatment). Participants with prior bendamustine treatment (> 12 months before the start of study treatment) are eligible if they meet the following criteria:\n\n  * Did not discontinue because of tolerability concerns.\n  * Achieved either partial response (PR) or complete response (CR) to the bendamustine regimen of at least 12 months in duration before relapse/progression.\n  * Experienced progression following a regimen containing an alkylating agent.\n* For participants to be treated with ibrutinib (Treatment C), prior treatment with a Bruton's tyrosine kinase (BTK) inhibitor.\n* Allogeneic stem cell transplant within the last 6 months or autologous stem cell transplant within the last 3 months before the date of the first dose of study treatment.\n* Active graft-versus-host disease following allogeneic transplant.\n* Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.",
    "miscellaneous_criteria": ""
}